Difference between revisions of "Antiphospholipid antibody syndrome"

Jump to navigation Jump to search
more
(create)
 
(more)
 
Line 1: Line 1:
'''Antiphospholipid antibody syndrome''', also '''antiphospholipid syndrome''', is a thingy commonly seen in the context of [[systemic lupus erythematosus]].<ref name=pmid9814675>{{Cite journal  | last1 = Asherson | first1 = RA. | title = The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | journal = Lupus | volume = 7 Suppl 2 | issue =  | pages = S55-62 | month =  | year = 1998 | doi =  | PMID = 9814675 }}</ref> It is commonly abbreviated '''APLA'''.
'''Antiphospholipid antibody syndrome''', also '''antiphospholipid syndrome''', is a thingy commonly seen in the context of [[systemic lupus erythematosus]].<ref name=pmid9814675>{{Cite journal  | last1 = Asherson | first1 = RA. | title = The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | journal = Lupus | volume = 7 Suppl 2 | issue =  | pages = S55-62 | month =  | year = 1998 | doi =  | PMID = 9814675 }}</ref> It is commonly abbreviated '''APLA'''.
==General==
Hypercoagulable state.
*See: ''[[Pulmonary_embolism#Risks_factors_.28VTE.29|Pulmonary embolism risk factors]]'' for the [[DDx]].


==Microscopic==
==Microscopic==
:See: ''[[Thrombotic microangiopathy#Microscopic|thrombotic microangiopathy]]''.
:See: ''[[Thrombotic microangiopathy#Microscopic|Thrombotic microangiopathy]]''.


==See also==
==See also==
48,453

edits

Navigation menu